HER2 Breast Cancer

FDA grants priority review for gedatolisib, a promising treatment for advanced HR+/HER2– breast cancer, showcasing significant efficacy in recent trials.

Sacituzumab govitecan shows promising overall survival trends in HR+/HER2− metastatic breast cancer, despite not meeting primary progression-free survival goals.

Fam-trastuzumab deruxtecan-nxki (T-DXd) promises enhanced outcomes for HER2-positive early breast cancer patients post-neoadjuvant treatment.

Ribociclib shows higher early treatment modifications than palbociclib in HR+/HER2– breast cancer, emphasizing the need for proactive toxicity management.

The approval is supported by findings from the phase 3 DESTINY-Breast09 trial.

Discover how the combination of palbociclib, trastuzumab, and endocrine therapy enhances survival in HER2-positive advanced breast cancer patients.

CAR T-cell therapy shows promise for treating HER2-positive breast cancer with CNS metastases, offering a novel approach to improve patient outcomes.

Advanced IHC assays enhance HER2-low breast cancer detection, improving treatment eligibility for trastuzumab deruxtecan.

SHR-A1811 is a novel HER2-targeting ADC comprised of trastuzumab linked to a topoisomerase I inhibitor payload via a cleavable linker.

Giredestrant and everolimus show significant survival benefits for ER-positive, HER2-negative advanced breast cancer post-CDK4/6 therapy.

SHR-A1811 shows significant antitumor activity in early-stage HER2+ breast cancer, both alone and with pyrotinib, promising improved treatment outcomes.

Gedatolisib shows promise in enhancing progression-free survival for HR+/HER2– breast cancer patients resistant to standard therapies, as revealed in ESMO 2025.

Experts at ESMO 2025 highlight antibody-drug conjugates in HER2-positive metastatic breast cancer treatment.

New data from the NATALEE trial reveals ribociclib significantly improves invasive disease-free survival in HR+/HER2– early breast cancer.

Recent trials reveal fam-trastuzumab deruxtecan-nxki's potential to transform treatment for patients with high-risk HER2-positive breast cancer, enhancing survival rates significantly.

The approval is supported by clinical findings from the EMBER-3 trial.

Explore the impact of CDK4/6 inhibitors in HR+/HER2– breast cancer treatment and the essential role of oncology pharmacy practice.

GLSI-100 shows promise in preventing HER2-positive breast cancer recurrence after standard therapy.

Patritumab deruxtecan shows promising efficacy in HR+/HER2– metastatic breast cancer, meeting key trial end points and highlighting its potential for advanced treatment.

Abemaciclib enhances overall survival in high-risk HR+, HER2– early breast cancer, establishing its role as a standard adjuvant therapy.

The study results could help bolster metformin as a potentially attractive option for patients with HER2-positive breast cancer.

A new study found that the natural alkaloids mitragynine and 7-hydroxymitragynine from Mitragyna speciosa showed stable binding and favorable drug-likeness as potential HER2 inhibitors in breast cancer.

Palbociclib revolutionizes HR+/HER2- breast cancer treatment, enhancing outcomes with endocrine therapies and promising new combinations for better patient care.

Research reveals that clinical stage significantly influences survival rates in HER2-positive breast cancer patients undergoing neoadjuvant chemotherapy.